Latest news on hep b cure

There is currently no cure for Hepatitis B (HBV), but there are several treatments available that can help manage the disease and reduce the risk of complications. Here are some of the latest developments and news on Hepatitis B treatment:

New treatments:

  1. Nucalimab: In 2020, the FDA approved nucalimab (Ofevzimab), a monoclonal antibody that targets the HBV surface antigen, for the treatment of chronic HBV infection in adults with compensated liver disease.
  2. Lamivudine-tenofovir combination: A study published in the New England Journal of Medicine in 2020 found that a combination of lamivudine and tenofovir disoproxil fumarate (TDF) was effective in suppressing HBV replication and reducing liver inflammation in patients with chronic HBV infection.
  3. Cenicriviroc: Cenicriviroc, a CCR5 antagonist, has shown promise in reducing HBV replication and liver inflammation in patients with chronic HBV infection.

Vaccine development:

  1. Hepatitis B vaccine for newborns: Researchers have developed a new vaccine that can provide long-term protection against HBV in newborns, which could potentially prevent mother-to-child transmission.
  2. Universal HBV vaccination: The World Health Organization (WHO) recommends universal HBV vaccination for all infants, and many countries have implemented vaccination programs.

Research updates:

  1. HBV cure through gene editing: Scientists have made progress in using gene editing technologies, such as CRISPR-Cas9, to cure HBV in animal models. While this technology is still in its early stages, it holds promise for developing a cure for HBV.
  2. HBV-specific T cells: Researchers have identified HBV-specific T cells that can recognize and kill HBV-infected cells, which could potentially be used as a treatment for HBV.
  3. HBV-neutralizing antibodies: Scientists have developed HBV-neutralizing antibodies that can recognize and neutralize HBV, which could potentially be used as a treatment for HBV.

Clinical trials:

  1. Phase III clinical trial for nucalimab: A phase III clinical trial is ongoing to evaluate the safety and efficacy of nucalimab in patients with chronic HBV infection.
  2. Phase II clinical trial for cenicriviroc: A phase II clinical trial is ongoing to evaluate the safety and efficacy of cenicriviroc in patients with chronic HBV infection.

Recent studies:

  1. Study on HBV treatment in patients with cirrhosis: A study published in the Journal of Hepatology in 2020 found that treatment with tenofovir disoproxil fumarate (TDF) and lamivudine was effective in reducing liver inflammation and improving liver function in patients with chronic HBV infection and cirrhosis.
  2. Study on HBV treatment in patients with liver cancer: A study published in the Journal of Clinical Oncology in 2020 found that treatment with sorafenib, a tyrosine kinase inhibitor, was effective in reducing HBV replication and improving survival in patients with liver cancer and chronic HBV infection.

These are just a few examples of the latest developments and news on Hepatitis B treatment. While there is no cure for HBV, ongoing research and clinical trials are working towards developing new and effective treatments for the disease.